New Experimental Drugs for the Treatment of Tuberculosis

New antitubercular agents are needed for two main purposes: to further simplify therapy (through reductions in the number of medicaments used, the number of doses administered, and the duration of treatment required), thus facilitating supervision and improving compliance, and to combat resistant my...

Full description

Saved in:
Bibliographic Details
Published in:Reviews of infectious diseases 1989-03, Vol.11, p.S479-S483
Main Author: PARENTI, F
Format: Article
Language:English
Subjects:
Animals
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibacterials
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antitubercular Agents - adverse effects
Antitubercular Agents - pharmacokinetics
Antitubercular Agents - therapeutic use
Antituberculars
Biological and medical sciences
Biological Availability
Chemotherapy
Dosage
Drug Resistance, Microbial
Drug Therapy, Combination
Fluoroquinolones
Future Directions and Priorities
Half lives
Humans
Lactams
Medical sciences
Medication administration
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Patient Compliance
Pharmacology. Drug treatments
Pulmonary tuberculosis
Rifamycins
Tuberculosis - drug therapy
Tuberculosis, Pulmonary - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New antitubercular agents are needed for two main purposes: to further simplify therapy (through reductions in the number of medicaments used, the number of doses administered, and the duration of treatment required), thus facilitating supervision and improving compliance, and to combat resistant mycobacteria. Reduction in the number of medicaments has been achieved by combining two or more drugs in a single tablet while retaining a degree of bioavailability similar to that of the single components. The adverse effects observed with once-weekly high doses of rifampin have limited the development of widely spaced intermittent regimens of treatment. For this reason new rifamycins have been developed that are as active as rifampin against mycobacteria but that also offer the advantage of high and prolonged serum levels and thus have the potential for once-weekly administration. The in vitro and in vivo properties of these drugs have been studied. Three classes of drugs show promise for the treatment of drug-resistant tuberculosis: spiropiperidyl rifamycin, the fluoroquinolones, and combinations of β-lactam agents and β-lactamase inhibitors.
ISSN:0162-0886